V
Vicebio
Multi-pathogen respiratory vaccines using Molecular Clamp technology
About Vicebio
Vicebio is a London-based clinical-stage biotechnology company developing next-generation vaccines against respiratory viral infections. Established in 2019, the company focuses on multivalent vaccines designed to protect against several respiratory pathogens with a single shot, with a particular emphasis on older adults and immunocompromised people, who carry much of the burden of severe respiratory disease.
Its work is built on the Molecular Clamp technology, developed at The University of Queensland by Professors Paul Young, Daniel Watterson and Keith Chappell and licensed exclusively from UniQuest, the university's commercialisation arm. The Molecular Clamp is a protein tag that locks viral surface proteins in their prefusion conformation, the shape they hold before infecting a cell. Stabilising proteins in this state is intended to trigger a strong protective immune response while simplifying manufacturing, making it possible to produce fully liquid, ready-to-use vaccines that can be stored at standard refrigerated temperatures.
The lead candidate, VXB-241, is a bivalent vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and has entered Phase 1 clinical testing. The pipeline also includes VXB-251, a preclinical trivalent candidate targeting RSV, hMPV and parainfluenza virus type 3. Because the platform is not based on mRNA, it offers an alternative modality, and the company sees potential applications across other viral families such as influenza and coronaviruses.
Vicebio is led by Emmanuel Hanon, a vaccine development specialist formerly at GSK Vaccines, with co-inventor Keith Chappell serving as Principal Scientist. The company now operates as part of Sanofi.
Source: Dealroom company dataOpen roles
Vicebio in the London ecosystem
The Vicebio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Medicxi
TCGX
venBio Partners
Avoro Capital Advisors
UniQuest Extension Fund
Goldman Sachs Asset Management
Series B and later7 investors entered at this stage
- TCTCGX
- TQThe University of Queensland
- UFUniQuest Extension Fund
- AAAvoro Capital Advisors
- VPvenBio Partners
- UNUniQuest
Goldman Sachs Asset Management
Source: Dealroom Talent Intelligence.
See Vicebio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Sanofi acquires Vicebio (December 2025)
